Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group

被引：2

作者：

Motomura, Kazuya ^{[1
]}

Sasaki, Keita ^{[2
]}

Sugii, Narushi ^{[3
]}

Yamaguchi, Shigeru ^{[4
]}

Inoue, Hirotaka ^{[5
]}

Oshima, Akito ^{[6
]}

Tanaka, Kazuhiro ^{[7
]}

Otani, Yoshihiro ^{[8
]}

Shirahata, Mitsuaki ^{[9
]}

Shibahara, Ichiyo ^{[10
]}

Nagane, Motoo ^{[11
]}

Tsuzuki, Shunsuke ^{[12
]}

Matsutani, Tomoo ^{[13
]}

Tsukamoto, Yoshihiro ^{[14
]}

Kijima, Noriyuki ^{[15
]}

Asano, Kenichiro ^{[16
]}

Ohno, Makoto ^{[17
]}

Inoue, Akihiro ^{[18
]}

Mineharu, Yohei ^{[19
]}

Miyake, Keisuke ^{[20
]}

Mitobe, Yuta ^{[21
]}

Hanihara, Mitsuto ^{[22
]}

Kawanishi, Yu ^{[23
]}

Deguchi, Shoichi ^{[24
]}

Saito, Masato ^{[25
]}

Matsuda, Ryosuke ^{[26
]}

Ujifuku, Kenta ^{[27
]}

Arita, Hideyuki ^{[28
]}

Sato, Yuichi ^{[29
]}

Yamashita, Shinji ^{[30
]}

Yonezawa, Ushio ^{[31
]}

Yamaguchi, Junya ^{[1
]}

Momii, Yasutomo ^{[32
]}

Ogawa, Takahiro ^{[33
]}

Kambe, Atsushi ^{[34
]}

Ohba, Shigeo ^{[35
]}

Fukai, Junya ^{[36
]}

Saito, Norihiko ^{[37
]}

Kinoshita, Masashi ^{[38
]}

Sumi, Koichiro ^{[39
]}

Otani, Ryohei ^{[40
]}

Uzuka, Takeo ^{[41
]}

Takebe, Noriyoshi ^{[42
]}

Koizumi, Shinichiro ^{[43
]}

Saito, Ryuta ^{[1
]}

Arakawa, Yoshiki ^{[19
]}

Narita, Yoshitaka ^{[17
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Neurosurg, 65 Tsurumai Co,Showa Ku, Nagoya, Japan

[2] JCOG Data Ctr, Natl Canc Ctr Hosp, Operat Off, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[3] Univ Tsukuba Hosp, Dept Neurosurg, 2-1-1 Amakubo, Tsukuba, Japan

[4] Hokkaido Univ, Fac Med, Dept Neurosurg, North 15,West 7,Kita Ku, Sapporo, Japan

[5] Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, 1-1-1,Honjo,Chuo Ku, Kumamoto, Japan

[6] Yokohama City Univ, Dept Neurosurg, 3-9 Fukuura, Kanazawa, Yokohama, Japan

[7] Kobe Univ Hosp, Dept Neurosurg, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Japan

[8] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Dept Neurol Surg, 2-5-1 Shikata Cho,Kita Ku, Okayama, Japan

[9] Med Univ Int Med Ctr, Dept Neurosurg Neurooncol, 1397-1 Yamane,Hidaka, Saitama, Saitama, Japan

[10] Kitasato Univ, Dept Neurosurg, Sch Med, 1-15-1,Minami Ku,Sagamihara, Kitasato, Japan

[11] Kyorin Univ, Fac Med, Dept Neurosurg, 6-20-2 Shinkawa, Tokyo, Japan

[12] Tokyo Womens Med Univ, Dept Neurosurg, 8-1 Kawada-Cho,Shinjuku Ku, Tokyo, Japan

[13] Chiba Univ, Grad Sch Med, Dept Neurol Surg, 1-8-1 Inohana,Chuou Ku, Chiba, Japan

[14] Niigata Univ, Brain Res Inst, Dept Neurosurg, 1-757 Asahimachi Dori,Chuo Ku, Niigata, Japan

[15] Osaka Univ, Grad Sch Med, Dept Neurosurg, 2-2 Yamadaoka,Suita, Osaka, Japan

[16] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Zaifu Cho 5, Hirosaki, Japan

[17] Natl Canc Ctr, Dept Neurosurg & Neurooncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[18] Ehime Uunivers, Sch Med, Dept Neurosurg, 454 Shitsukawa, Toon, Ehime, Japan

[19] Kyoto Univ, Grad Sch Med, Dept Neurosurg, 54 Kawahara Cho,Shogoin Sakyo Ku, Kyoto, Japan

[20] Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Ikenobe,Miki Cho, Kagawa, Japan

[21] Yamagata Univ Hosp, Dept Neurosurg, 2-2-2 Iida-Nishi, Yamagata, Japan

[22] Univ Yamanashi, Dept Neurosurg, 1110 Shimokato, Kofu, Yamanashi, Japan

[23] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Oko Cho,Nanko Ku, Kohasu, Kochi, Japan

[24] Shizuoka Canc Ctr, Dept Neurosurg, Shimonagakubo 1007, Nagaizumi, Shizuoka, Japan

[25] Asahikawa Med Univ, Dept Neurosurg, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Japan

[26] Nara Med Univ, Dept Neurosurg, Shijo Cho 840, Kashihara, Nara, Japan

[27] Nagasaki Univ, Grad Sch Biomed Sci, Dept Neurosurg, 1-7-1 Sakamoto, Nagasaki, Japan

[28] Osaka Int Canc Inst, Dept Neurosurg, 3-1-69, Otemae, Chuo Ku, Osaka, Japan

[29] Iwate Med Univ, Sch Med, Dept Neurosurg, 2-1-1 Idai Dori, Shiwa, Iwate, Japan

[30] Miyazaki Univ, Dept Neurosurg, 5200 Kihara Kiyotake, Miyazaki, Japan

[31] Hiroshima Univ Hosp, Dept Neurosurg, 1-2-3 Minami Ku, Kasumi, Hiroshima, Japan

[32] Oita Univ, Fac Med, Dept Neurosurg, 1-1 Idaigaoka Hasama Machi, Yufu, Oita, Japan

[33] Kyoto Prefectural Univ Med, Dept Neurosurg, 465 Kajii Cho,Kawaramachi-Hirokoji,Kamigyo Ku, Kyoto, Japan

[34] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurosurg, 36-1 Nishi Cho, Yonago, Tottori, Japan

[35] Fujita Hlth Univ, Dept Neurosurg, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[36] Wakayama Med Univ, Sch Med, Dept Neurol Surg, 811-1 Kimiidera, Wakayama, Japan

[37] Toho Univ, Ohashi Med Ctr, Dept Neurosurg, 2-22-36 Ohashi, Meguro, Tokyo, Japan

[38] Kanazawa Univ, Dept Neurosurg, 13-1 Takara Machi, Kanazawa, Japan

[39] Nihon Univ, Sch Med, Dept Neurol Surg, 30-1 Oyaguchikamicho,Itabashi Ku, Tokyo, Japan

[40] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Neurosurg, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo, Japan

[41] Dokkyo Med Univ Hosp, Dept Neurosurg, 880 Kitakobayashi,Mibu Machi, Tochigi, Japan

[42] Med Res Inst Kitano Hosp, Dept Neurosurg, PIIF Tazuke Kofukai, 2-4-20 Ohgimachi,Kita-Ku, Osaka, Japan

[43] Hamamatsu Univ Sch Med, Dept Neurosurg, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 10期

关键词：

glioblastoma; primary central nervous system lymphoma; treatment regimen; high-cost medical care; cost; HIGH-DOSE METHOTREXATE; RANDOMIZED PHASE-III; CHEMOTHERAPY; TEMOZOLOMIDE; GLIOBLASTOMA; RADIOTHERAPY; TRIAL; BEVACIZUMAB; CONCOMITANT; RITUXIMAB;

D O I：

10.1093/jjco/hyae116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved.Methods We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL.Results The most used regimen (46.8%) for GBM in patients aged <= 74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month).Conclusions Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors. As regimens used in GBM or PCNSL are costly, we believe that it will be necessary in the future to take cost-effectiveness into consideration in selecting a treatment.

引用

页码：1123 / 1131

页数：9

共 50 条

[1] Randomized controlled trial on malignant brain tumors - Activities of the Japan Clinical Oncology Group-Brain Tumor Study Group
Shibui, S
NEUROLOGIA MEDICO-CHIRURGICA, 2004, 44 (04) : 220 - 221
[2] CHILDHOOD BRAIN-TUMOR INVESTIGATIONS - PEDIATRIC ONCOLOGY GROUP
KUN, LE
NORRIS, DG
BOYETT, J
JOURNAL OF NEURO-ONCOLOGY, 1986, 4 (01) : 108 - 108
[3] CLINICAL TRIALS FOR MALIGNANT BRAIN TUMORS CONDUCTED BY JCOG-BRAIN TUMOR STUDY GROUP
Shibui, Soichiro
Kayama, Takamasa
Wakabayashi, Toshihiko
Nishikawa, Ryo
NEURO-ONCOLOGY, 2010, 12 : 74 - 74
[4] A BRAIN-TUMOR SUPPORT GROUP
WHITEHEAD, HL
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 1991, 13 (03) : 431 - 432
[5] RESULTS OF THE BRAIN-TUMOR STUDY-GROUP
DEUTSCH, M
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 : 122 - 122
[6] CHEMOTHERAPY OF MALIGNANT GLIOMAS - RESULTS OF THE EORTC BRAIN-TUMOR GROUP-STUDY
HILDEBRAND, JG
REVUE NEUROLOGIQUE, 1992, 148 (6-7) : 435 - 440
[7] BRAIN-TUMOR RESEARCH-CENTER AND NORTHERN CALIFORNIA ONCOLOGY GROUP - NEW TREATMENT REGIMENS FOR MALIGNANT GLIOMAS AND OTHER PRIMARY BRAIN-TUMORS
LEVIN, VA
GUTIN, P
WILSON, CB
JOURNAL OF NEURO-ONCOLOGY, 1986, 4 (01) : 108 - 108
[8] A REVIEW OF STUDIES OF THE EORTC BRAIN-TUMOR GROUP
HILDEBRAND, J
CANCER TREATMENT REPORTS, 1981, 65 : 89 - 94
[9] GROUP FORMED TO HELP BRAIN-TUMOR VICTIMS
不详
CANADIAN FAMILY PHYSICIAN, 1986, 32 : 235 - 236
[10] THE PROGNOSTIC IMPORTANCE OF TUMOR SIZE IN MALIGNANT GLIOMAS - A COMPUTED TOMOGRAPHIC SCAN STUDY BY THE BRAIN-TUMOR COOPERATIVE GROUP
WOOD, JR
GREEN, SB
SHAPIRO, WR
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (02) : 338 - 343

← 1 2 3 4 5 →